Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 14/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22092081 | 0.85 | GPR139 (0.38) | GPR139EGFRRAF1KDRMAP2K2 | |
| SCHEMBL22206423 | 0.85 | GPR139 (0.46) | GPR139PDE10AKDM4ERXFP1NPC1 | |
| SCHEMBL22092278 | 0.80 | GPR139 (0.47) | GPR139PDE10A | |
| SCHEMBL29124232 | 0.78 | CA1 (0.36) | NPC1AAK1EGFRRAF1KDR | |
| SCHEMBL22092249 | 0.76 | GPR139 (0.48) | GPR139PDE10AKDM4ERXFP1 | |
| SCHEMBL22206482 | 0.75 | HDAC10 (0.35) | NPC1EGFRRAF1KDRMAP2K2 | |
| SCHEMBL22092244 | 0.75 | FGFR3 (0.41) | GPR139KDR | |
| Trifluoroacetic Acid SCHEMBL22092129 | 0.74 | GPR139 (0.45) | GPR139PDE10AKDM4ERXFP1 | |
| SCHEMBL29267573 | 0.74 | CYP2C19 (0.33) | GPR139ALDH1A1 | |
| SCHEMBL29267547 | 0.74 | CYP2C19 (0.35) | GPR139KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | disclosed |
| US-20220024918-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-01-27 | — | — | US | disclosed |
| US-11091479-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-08-17 | — | — | US | disclosed |
| US-20200223844-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091479-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | VAPB, HDLBP, VAPA | GPR139 4033/4885PDE10A 4028/4885KDM4E 4294/4885 |
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | VAPB, HDLBP, VAPA | GPR139 4033/4885PDE10A 4028/4885KDM4E 4294/4885 |
| US-20200223844-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPB, HDLBP, VAPA | GPR139 4033/4885PDE10A 4028/4885KDM4E 4294/4885 |
| US-20220024918-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPB, HDLBP, VAPA | GPR139 4033/4885PDE10A 4028/4885KDM4E 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.